New Collaboration Focuses on PRPF31 Gene Therapy
For the inherited retinal disease (IRD) community, industry partnerships represent vital steps forward in the journey toward effective treatments. According to a press release from Mass General Brigham, Massachusetts Eye and Ear has entered into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration.
Key Details of the Licensing Agreement
Under the terms of the agreement, the collaboration will focus on addressing inherited retinal degenerations caused by mutations in the PRPF31 gene. These specific mutations are recognized as one of the common causes of autosomal dominant retinitis pigmentosa.
Previous laboratory research conducted by members of the Ocular Genomics Institute at Mass Eye and Ear demonstrated that adeno-associated virus (AAV)-mediated gene augmentation therapy can successfully restore normal function to PRPF31 mutant cells. Building upon this foundation, Biogen will hold an exclusive worldwide license to further develop the product.
Moving Toward Clinical Development
As part of the agreement, Biogen is slated to take responsibility for all U.S. Food and Drug Administration (FDA) required investigational new drug (IND) enabling studies, alongside future clinical development and commercialization efforts.
While further studies are required before the therapy reaches patients, this partnership marks an important progression for laboratory discoveries moving closer to formal clinical evaluation. The IRD community will continue to monitor updates as Biogen and Mass Eye and Ear advance their work on PRPF31-associated retinal degeneration.